These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1498 related items for PubMed ID: 25018121

  • 1. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM, Povedano ST, Forst T, González JG, Atisso C, Sealls W, Fahrbach JL.
    Lancet; 2014 Oct 11; 384(9951):1349-57. PubMed ID: 25018121
    [Abstract] [Full Text] [Related]

  • 2. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
    Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z.
    Lancet; 2015 May 23; 385(9982):2057-66. PubMed ID: 26009229
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.
    Lancet; 2018 Nov 17; 392(10160):2180-2193. PubMed ID: 30293770
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ.
    Diabetes Obes Metab; 2017 Apr 17; 19(4):524-536. PubMed ID: 27981757
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
    Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T.
    Diabetes Obes Metab; 2015 Oct 17; 17(10):994-1002. PubMed ID: 26179754
    [Abstract] [Full Text] [Related]

  • 6. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.
    Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T.
    Diabetes Obes Metab; 2015 Oct 17; 17(10):974-83. PubMed ID: 26179187
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
    Wang W, Nevárez L, Filippova E, Song KH, Tao B, Gu L, Wang F, Li P, Yang J.
    Diabetes Obes Metab; 2019 Feb 17; 21(2):234-243. PubMed ID: 30129089
    [Abstract] [Full Text] [Related]

  • 8. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z.
    Lancet Diabetes Endocrinol; 2018 May 17; 6(5):370-381. PubMed ID: 29483060
    [Abstract] [Full Text] [Related]

  • 9. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
    Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT.
    Lancet Diabetes Endocrinol; 2018 Aug 17; 6(8):605-617. PubMed ID: 29910024
    [Abstract] [Full Text] [Related]

  • 10. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
    Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T.
    Diabetes Obes Metab; 2016 Mar 17; 18(3):249-57. PubMed ID: 26661514
    [Abstract] [Full Text] [Related]

  • 11. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T.
    Lancet; 2023 Aug 12; 402(10401):529-544. PubMed ID: 37385280
    [Abstract] [Full Text] [Related]

  • 12. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM, Weitgasser R, Perez Manghi F, Pintilei E, Fahrbach JL, Jiang HH, Shell J, Robertson KE.
    Diabetes Obes Metab; 2016 May 12; 18(5):475-82. PubMed ID: 26799540
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
    Chen YH, Huang CN, Cho YM, Li P, Gu L, Wang F, Yang J, Wang WQ.
    Diabetes Obes Metab; 2018 Sep 12; 20(9):2121-2130. PubMed ID: 29708650
    [Abstract] [Full Text] [Related]

  • 14. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N, Giorgino F.
    Diabetes Obes Metab; 2018 Feb 12; 20(2):409-418. PubMed ID: 28817231
    [Abstract] [Full Text] [Related]

  • 15. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P, Norwood P, Jódar E, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z.
    Diabetes Obes Metab; 2017 Jul 12; 19(7):1024-1031. PubMed ID: 28294499
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z.
    Diabetes Care; 2014 Aug 12; 37(8):2149-58. PubMed ID: 24742660
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
    Xue X, Ren Z, Zhang A, Yang Q, Zhang W, Liu F.
    Int J Clin Pract; 2016 Aug 12; 70(8):649-56. PubMed ID: 27456750
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
    Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z.
    Diabetes Obes Metab; 2015 Sep 12; 17(9):849-58. PubMed ID: 25912221
    [Abstract] [Full Text] [Related]

  • 19. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á.
    Lancet; 2021 Aug 14; 398(10300):583-598. PubMed ID: 34370970
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 75.